The Arizona State Retirement System acquired a new position in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) in the fourth quarter, HoldingsChannel reports. The company bought 7,825 shares in the company valued at approximately $ 325.0.
Other hedge funds and other institutional investors have also bought and sold shares in the company. HM Payson & Co. bought a new stake in Relay Therapeutics in the 3rd quarter valued at approximately $ 37.0. Pacer Advisors Inc. bought a new position in Relay Therapeutics in the fourth quarter valued at approximately $ 98 , 0. Platinum Investment Management Ltd. bought a new position in Relay Therapeutics shares valued at approximately $ 98.0 in the third quarter. Nisa Investment Advisors LLC bought a new position in Relay Therapeutics shares valued at approximately $ 85.0 during the fourth quarter. Finally, M&T Bank Corp bought a new position in Relay Therapeutics shares in the third quarter valued at approximately $ 219. 0. 98. 33% of the shares are owned by institutional investors and hedge funds.
In other news, major shareholder Rock Ventures Iii LP Third sold 1,500,0 shares of Relay Therapeutics’ shares in a transaction on Tuesday, January th. The stock was sold at an average price of $). , for a total transaction of $ 60.0, 0. 000. The transaction was announced in a filing with the Securities & Exchange Commission, which can be accessed via this link. General Counsel Brian Adams also sold 5.0 shares of Relay Therapeutics in a transaction on Thursday, January 28th. The stock was sold at an average price of $ 43, for a total value of $ 250,250. Following the sale, the General Counsel now directly owns .0 shares of the company valued at approximately $ 825,750. The disclosure for that sale can be found here. Insiders owned 3,304 shares in the company valued at $ 85,852,304 over the past ninety days.
Shares of Relay Therapeutics stock opened at $ 33.55 on Mondays. The company’s simple moving average for fifty days is $ 36.05. Relay Therapeutics, Inc. has a 1-year low of $ 15.47 and a 1-year high of $ 64.29.
RLAY has been the subject of several analyst reports. Zacks Investment Research downgraded Relay Therapeutics’ shares from a “buy” rating to a “hold” rating on Friday January 8th in a research note. JMP Securities announced in a research on Tuesday, December 8th Note initiated reporting on Relay Therapeutics’ stocks. They gave an “Outperform” rating and a $ 57 price target for the company. JPMorgan Chase & Co. raised its target price on shares of Relay Therapeutics from $ 56. to $ 37. and rated the company on Friday, January in a research note with a “neutral” th. Finally, HC Wainwright gave a buy rating again and issued a $). Target price (of $ 56.) On shares of Relay Therapeutics in a research note on Tuesday, December 00th. Two investment analysts have rated the stock with a hold rating and five with a buy rating. Relay Therapeutics has an average rating of “Buy” and a consensus price target of $ 52.61.
About Relay Therapeutics
Relay Therapeutics, Inc is a precision clinical-stage drug company. It looks at transforming the drug discovery process and initially focuses on improving therapeutic small molecule discovery in targeted oncology. Its product candidates include RLY – 1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2), which is in phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY – 4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors with oncogenic FGFR2 changes; and RLY-PI3K 1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide-3-kinase alpha.
Highlighted Story: Understanding Analyst Reviews
Would you like to see what other hedge funds are holding on to RLAY? Visit HoldingsChannel.com for the latest information on 13 F filings and insider trading for Relay Therapeutics, Inc. (NASDAQ: RLAY).
Receive news and reviews for Relay Therapeutics daily – Enter your email address below to receive a brief daily summary of the latest news and analysts’ ratings for Relay Therapeutics and related companies with IMS Magazine’s FREE daily email newsletter.